Last reviewed 2026-05-19 · How we verify

Dexpure (dexrabeprazole)

unknown active ✓ Verified May 2026

Dexpure (generic name: dexrabeprazole) is a Proton Pump Inhibitors drug. It is currently in unknown development for Duodenal Ulcer due to H. Pylori, Duodenal ulcer disease, Erosive esophagitis.

Dexpure works by irreversibly inhibiting the H+/K+ ATPase enzyme in the stomach lining, reducing acid production.

Dexpure (dexrabeprazole) is a proton pump inhibitor (PPI) small molecule developed to target the proto-oncogene tyrosine-protein kinase receptor Ret. It is used to treat various gastrointestinal conditions, including duodenal ulcers, erosive esophagitis, and gastroesophageal reflux disease. The commercial status of Dexpure is currently unknown, and it has not been approved by the FDA. Key safety considerations include potential interactions with other medications and the risk of osteoporosis with long-term use. Dexpure works by reducing stomach acid production.

At a glance

Generic name	dexrabeprazole
Drug class	Proton Pump Inhibitors
Target	Proto-oncogene tyrosine-protein kinase receptor Ret
Therapeutic area	Gastroenterology
Phase	unknown

Mechanism of action

Imagine your stomach lining is like a factory that produces acid to help digest food. Dexpure blocks the acid-producing factories, reducing the amount of acid produced and helping to heal stomach ulcers and other conditions.

Approved indications

Duodenal Ulcer due to H. Pylori
Duodenal ulcer disease
Erosive esophagitis
Gastric Hypersecretory Conditions
Gastric ulcer
Gastroesophageal reflux disease
Maintenance of Healing Erosive Esophagitis
Pathological Gastric Hypersecretory Condition
Peptic reflux disease
Peptic ulcer
Zollinger-Ellison syndrome

Common side effects

No common side effects on file.

Drug interactions

clopidogrel
dasatinib
delavirdine
erlotinib
nelfinavir
ponatinib
rilpivirine
risedronic acid

Key clinical trials

The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dexpure CI brief — competitive landscape report
Dexpure updates RSS · CI watch RSS
portfolio CI

Frequently asked questions about Dexpure

What is Dexpure?

Dexpure (dexrabeprazole) is a Proton Pump Inhibitors drug, indicated for Duodenal Ulcer due to H. Pylori, Duodenal ulcer disease, Erosive esophagitis.

How does Dexpure work?

Dexpure works by irreversibly inhibiting the H+/K+ ATPase enzyme in the stomach lining, reducing acid production.

What is Dexpure used for?

Dexpure is indicated for Duodenal Ulcer due to H. Pylori, Duodenal ulcer disease, Erosive esophagitis, Gastric Hypersecretory Conditions, Gastric ulcer.

What is the generic name of Dexpure?

dexrabeprazole is the generic (nonproprietary) name of Dexpure.

What drug class is Dexpure in?

Dexpure belongs to the Proton Pump Inhibitors class. See all Proton Pump Inhibitors drugs at /class/proton-pump-inhibitors.

What development phase is Dexpure in?

Dexpure is in unknown.

What does Dexpure target?

Dexpure targets Proto-oncogene tyrosine-protein kinase receptor Ret and is a Proton Pump Inhibitors.

Drug class: All Proton Pump Inhibitors drugs
Target: All drugs targeting Proto-oncogene tyrosine-protein kinase receptor Ret
Manufacturer: — full pipeline
Therapeutic area: All drugs in Gastroenterology
Indication: Drugs for Duodenal Ulcer due to H. Pylori
Indication: Drugs for Duodenal ulcer disease
Indication: Drugs for Erosive esophagitis

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing